1. ESMOupdate 2012, Lung Cancer

Dr. med. Walter Mingrone und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Lymphoma, Myeloma and CNS Tumors, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
How to select amongst available options for the treatment of advanced RCC; B. Escudier

LBA8_PR: Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial; R. J. Motzer et al (2. Link)

Poster 1233: Efficacy and Patient (PT)- reported outcomes (pros) with Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-mutant advanced non-small cell lung cancer (NSCLC): a randomized, phase II trial; Janne et al.

Leave a Reply

Your email address will not be published. Required fields are marked *